This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
The aim of this study was to perform an economic evaluation of the DHOPE-DCD trial, which investigated hypothermic oxygenated machine perfusion versus static cold preservation in liver transplant recipients receiving livers from donors after circulatory death.
Participants in the original trial were randomised to either receive liver preserved with hypothermic oxygenated machine perfusion following static cold preservation or with static cold preservation alone.
156 liver transplant recipients that obtained from a donor after circulatory death that were included in the DHOPE-DCD trial.
The main outcomes of interest were costs per healthcare activity, costs for machine perfusion, transplant-related healthcare costs, mean reduction in cost per patient for the 3 cost scenarios, minimal number of procedures needed per year for cost-effectiveness.
N/A.
This manuscript reports an economic evaluation from the Dutch centres participating in the DHOPE-DCD randomised controlled trial. The authors looked at 3 scenarios: (1) cost for the device and consumables only, (2) costs for device and personnel, (3) costs for device, personnel and depreciation. They found that the use of D-HOPE reduced the cost of medical care in the first year post-transplant, mainly due to a reduction in ITU and intervention costs. D-HOPE achieves cost effectiveness after 30 procedures/year when personnel and depreciation costs were accounted for. This study highlights the importance of considering personnel costs, infrastructure and logistics when evaluating machine perfusion technology. In high-volume DCD transplant centres, the use of D-HOPE with a dedicated perfusion team is likely to be cost-effective, whereas in smaller volume centres it will only prove cost effective if perfusion is managed by existing staff within existing facilities. Further studies will be required to see if these findings will generalise to other healthcare settings.
ClinicalTrials.gov - NCT02584283.
No funding received.
This study aims to examine effect of liver transplantation combined with chemotherapy on overall survival among patients with permanently unresectable colorectal liver metastases.
Participants were randomly assigned to receive either liver transplantation plus chemotherapy or to chemotherapy alone.
94 adult patients (18–65 years) with permanently unresectable colorectal liver metastases.
The primary outcome was overall survival at 5 years. Secondary outcomes were overall survival at 3 years, progression-free survival and recurrence rate at 3 and 5 years and health-related quality of life.
5 years.
This manuscript reports the outcomes from TransMet, a multicentre European open-label RCT comparing a combination of liver transplantation (LT) and chemotherapy to chemotherapy alone in patients with unresectable colorectal liver metastases and no extrahepatic disease. 94 patients were randomised, of whom 20 patients (11 in the LT and 9 in the chemotherapy group) did not receive the randomised treatment. In intent-to-treat analysis, the hazard ratio for overall 5-year survival was 0.37 (95% CI 0.21–0.65) in favour of transplantation. There were no obvious differences in the incidence of adverse events, and quality of life was similar in the two groups during follow-up. These results are impressive and suggest a significant benefit to transplantation in carefully selected patients. Methodology is good and the study is clearly reported. The findings are limited to patients with partial response or stable disease after chemotherapy, and patients with BRAF mutations were excluded. It requires prioritisation of this patient cohort in organ allocation policy to ensure expedited transplant.
3.
Strict intention-to-treat analysis.
Yes.
ClinicalTrials.gov - NCT02597348.
Non-industry funded.
This exciting paper presents significant findings regarding the management of patients with unresectable colorectal liver metastases (CRLM). The clinical implications of this research are potentially profound.
Less than 30% of patients with CRLM are thought to be resectable. Traditionally, patients with unresectable CRLM face a poor prognosis, typically receiving chemotherapy without curative potential. This study challenges the
The study was a multicentre, open-label, prospective, randomised controlled trial done in 20 tertiary centres in Europe, including 94 patients randomised 1:1 between control and study arms, and stratified by centre. The liver transplantation plus chemotherapy group underwent liver transplantation within 2 months of the last chemotherapy cycle. Transplanted patients received a tailored immunosuppression regimen with postoperative chemotherapy. The control arm continued on chemotherapy. In cases of progression while on the transplant waiting list, chemotherapy was restarted, and the patient was temporarily suspended from transplantation until disease control was achieved. The primary endpoint was 5-year survival (presented in intention-to-treat and per-protocol analysis).
Intention to treat analysis showed a clinically significant difference in overall survival at 5 years: 57% for liver transplantation plus chemotherapy versus 13% for chemotherapy alone (HR 0.37 [95% CI 0.21–0.65]; p = 0.0003). The impact of liver transplantation was even greater in per protocol analysis. A similarly high proportion of patients had an adverse event in both groups (80% versus 83%).
The randomised nature of this trial, and the intention-to-treat analysis circumvents the confounding element of prior publications in this field, where patients with better prognosis may have been selected for liver transplantation over chemotherapy alone.
In summary, these findings could significantly impact clinical practice by redefining treatment pathways for patients with unresectable CRLM. This trial highlights the importance of innovative treatment strategies and the need for multidisciplinary approaches in complex cases of liver metastases.
All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication.
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author(s) declare that no Generative AI was used in the creation of this manuscript.
Edited by Reshma Rana Magar.